Litcius/Paper detail

Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (LBA 4)

Ursula A. Matulonis, Domenica Lorusso, Ana Oaknin, Sandro Pignata, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason Konner, Margarita Romeo Marin, Philipp Harter, Conleth G. Murphy, Jiuzhou Wang, Elizabeth Noble, Brooke Esteves, Michael Method, Robert E. Coleman

2022Gynecologic Oncology21 citationsDOI

Topics & Concepts

MedicineInternal medicineClinical endpointTolerabilityOvarian cancerBevacizumabPhases of clinical researchOncologyGastroenterologyAdverse effectSurgeryCancerToxicityClinical trialChemotherapyOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyRenal cell carcinoma treatment
Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (LBA 4) | Litcius